Sundaram, N; Chen, C; Yoong, J; Luvsan, ME; Fox, K; Sarankhuu, A; La Vincente, S; Jit, M (2017) Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2016.12.070

Downloaded from: http://researchonline.lshtm.ac.uk/3423753/

DOI: 10.1016/j.vaccine.2016.12.070

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia

Neisha Sundaram, Cynthia Chen, Joanne Yoong, Munkh-Erdene Luvsan, Kimberley Fox, Amarzaya Sarankhuu, Sophie La Vincente, Mark Jit

Objective: The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of introducing PCV13 compared to no PCV vaccination in Mongolia.

Methods: The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple cohort model. The risk of various clinical presentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive pneumococcal disease and acute otitis media) at all ages for thirty birth cohorts was assessed. The analysis considered both health system and societal perspectives. A 3+0 vaccine schedule and price of US $3.30 per dose was assumed for the baseline scenario based on Gavi, the Vaccine Alliance’s advance market commitment tail price.

Results: The ICER of PCV13 introduction is estimated at US$52 per disability-adjusted life year (DALY) averted (health system perspective), and cost-saving (societal perspective). Although indirect effects of PCV have been well-documented, a conservative scenario that does not consider indirect effects estimated PCV13 introduction to cost US$79 per DALY averted (health system perspective), and US$19 per DALY averted (societal perspective). Vaccination with PCV13 is expected to cost around US$920,000 in 2016, and thereafter US$820,000 every year. The programme is likely to reduce direct disease-related costs to MOH by US$440,000 in the first year, increasing to US$10,000 by 2025.

Conclusion: Introducing PCV13 as part of Mongolia’s national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-quality national data would improve future economic analyses for vaccine introduction.
1. Background

*Streptococcus pneumoniae* caused an estimated 500,000 deaths worldwide among children under five years of age in 2008 [1]. In Mongolia, pneumonia is a leading cause of childhood mortality, as well as accounting for 51% of all-age respiratory disease admissions [2]. Severe air pollution, especially in winter, exacerbates the problems caused by pneumonia and other acute respiratory infections [3]. Shortage of equipment, drugs and skilled health professionals, mostly in rural areas, further contribute to high preventable mortality from pneumonia [4], *S. pneumoniae* and *Haemophilus influenzae* type b (Hib) are leading causes of childhood pneumonia-related deaths [5] and cause a substantial portion of meningitis and sepsis, in the absence of vaccination. Since introduction of Hib vaccine in 2005 in Mongolia [6], the continuing high rate of childhood pneumonia is attributable to pneumococcus more than any other single cause.

In accordance with World Health Organization (WHO) recommendations to include pneumococcal conjugate vaccines (PCVs) in childhood immunization programs worldwide [1], Mongolia plans to introduce the 13-valent PCV (PCV13) into its Expanded Programme on Immunisation in a 3 + 0 schedule (three primary doses at 2, 3 and 4 months of age without a booster dose) that would coincide with the oral polio and pentavalent vaccine schedules [7]. PCV13 (or Prevnar-13®) protects against invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) from *S. pneumoniae*.

The pneumococcal Advance Market Commitment (AMC) is an innovative funding mechanism incentivising vaccine makers to produce affordable vaccines for the world's poorest countries. Ministry of Health (MOH), Mongolia applied to Gavi, the Vaccine Alliance (Gavi) in 2013 to purchase PCV13 through the AMC mechanism and received Gavi approval in March 2014 for PCV introduction starting in 2016, with the intent of scaling up to a nationwide programme. Although Mongolia’s current Gross National Income (GNI) per capita is above Gavi’s threshold and the country is therefore transitioned out of Gavi support in 2016, it remains eligible for PCV vaccine prices under the AMC even after being fully self-financed [8]. However, introduction of PCV will still require financing to cover costs of vaccine purchase and vaccination within the immunization programme. Mongolia’s government has thus identified the need to assess the cost-effectiveness and financial sustainability of PCV13 introduction in the Mongolian context [7].

A collaboration between MOH, local and foreign investigators was established to conduct an economic evaluation for PCV introduction to inform decision making and establish the case for sustained investment. This evaluation is the first country-specific study to assess the costs and outcomes associated with PCV13, in order to determine whether PCV13 is cost-effective to introduce as part of Mongolia’s national immunisation programme, as well as its likely budget impact.

2. Methods

2.1. Model overview and analytic framework

In order to investigate the value for money and financial sustainability respectively of vaccination the incremental cost-effectiveness of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple-cohort model (Fig. 1). The model assesses the risk of various clinical presentations of pneumococcal disease—meningitis (including sequelae), pneumonia, non-pneumonia non-meningitis (NPNM) IPD and AOM—for each year of life between 0 and 100, in both vaccinated and unvaccinated individuals, and both with and without a vaccination programme. Each disease episode is associated with a cost and health utility loss. Thirty consecutive birth cohorts were assessed over a thirty year time period. The direct effect of PCV (direct population effects) is assessed by a proportionate reduction in pneumococcal disease risk in vaccinated individuals. The indirect effects of PCV introduction—herd protection (referring to a lower risk of infection among unvaccinated individuals due to increase in population-level immunity, generated by reduction in carriage of vaccine serotypes) and serotype replacement (a phenomenon referring to an increase in incidence of invasive disease caused by non-vaccine serotypes and proportion of carriage of non-vaccine serotypes after vaccine introduction)—are also considered by an adjustment to disease risk in unvaccinated individuals in the presence of a population-wide vaccination programme. Although there is substantial evidence for the existence of these indirect effects from post-introduction surveillance [9,10], the magnitude of such effects is uncertain, so we considered an alternative conservative scenario without indirect effects.

The budget impact analysis was conducted over a 10 year horizon. For each year of the analysis, costs were calculated from net costs from all modelled birth cohorts (including adult cohorts affected by indirect vaccine effects) that were born in the same or previous years. All direct costs were assumed to be included in the budget impact; indirect societal costs were also shown in a sensitivity analysis.

Costs were inflated to 2014 prices based on Mongolia’s inflation rate of 15.0% in 2012 and 8.6% in 2013 [11]. Costs were then converted into United States (US) dollars using the average exchange rate for the year 2014 between the US dollar (US$) and the Mongolian tugrik (MNT): 1 US$ = 1804.50 MNT. Future costs and outcomes were discounted from the first year of vaccination at 3% per annum [12]. The analysis was done from the perspective of both the health system and society. Health system costs included vaccine costs (purchase, freight and administration), cold chain, surveillance, and hospitalization or health centre consultation costs. Societal costs considered productivity losses and out-of-pocket expenses in addition to health system costs noted above. Table 1 shows base case parameters used in the model.

2.2. Demographics

Population estimates for 2012 stratified by year of age were obtained in hard copy from the National Statistical Office, Mongolia and life expectancies were obtained from WHO’s 2011 Life Tables for Mongolia [13].

2.3. Vaccine coverage

A 3 + 0 schedule with vaccine coverage of 98.2% and 97.6% for first and third dose, respectively, was assumed, based on administrative coverage data of diphtheria-tetanus-pertussis vaccine given at the same ages [14]. Second dose coverage was assumed to be the average of the first and third doses. In addition, buffer stock of 25% of first dose coverage and 2% wastage (based on wastage for pentavalent vaccine communicated through the Expanded Programme on Immunization) was assumed.

2.4. Vaccine cost

A per-dose cost of $3.30 was used, since Mongolia is eligible to purchase pneumococcal vaccines at the Gavi AMC ‘tail price’ [8] set at $3.30 from 2014 onwards based on the third AMC supply agreement (22 July 2013) [15]. An additional 4% was added to account for vaccine freight as well as $0.0605 and $0.008 per dose for...
syringe and safety box purchase, respectively [16]. Customs and handling costs at 19% were included [16]. The cost of 5 min of a nurse’s time $229.27/month (413,720 MNT/month) based on a nurse’s average salary was further assumed.

Cold chain costs included purchases of refrigerators (at approximately $1000 per unit) to store vaccine doses at the central level and in the provinces based on a quarterly procurement of PCV13 [17]. Surveillance for pneumococcal disease has already been established in Mongolia, so only incremental annual maintenance costs of $100,738 were included to cover costs for centralized specimen testing and data management, based on past WHO-funded surveillance activities.

2.5. Vaccine efficacy

Efficacy of 9-valent PCV with a 3 + 0 schedule in HIV negative patients from a South African trial (83%) [18] was used as HIV prevalence in Mongolia is very low [19]. Efficacy data from a study in Gambia was not used as they were not stratified by HIV status [20]. However, PCV13 has shown poor efficacy against IPD associated with serotype 3, ranging from 68% in the USA [21] to non-significant in England [22]. Hence, an overall efficacy of 34% against serotype 3 IPD was assumed. We also assumed that 1.03% of vaccine type IPD was caused by serotype 3 based on estimates for Asia [23]. Efficacy against vaccine type IPD was thus scaled down to 82.5%. Vaccine efficacy of 20.2% against all-cause AOM was assumed [24], by scaling up PCV10 vaccine efficacy of 19% in the most recent trial (COMPAS) [24] to include the contribution of PCV13 against serotypes 6A and 19A. Average vaccine duration of protection of 8.3 years was assumed as with previous modelling work [25]. It was conservatively assumed that three doses were required for protection.

Distribution of serotypes was based on the Pneumococcal Global Serotype Project, where proportion of IPD due to each serotype for Asia were used [23]. No reliable carriage data for Mongolia were available, so instead used data from a study of nasopharyngeal swabs of children visiting outpatient clinics in Kazakhstan, Uzbekistan and Kyrgyz Republic [26].

2.6. Disease burden

Incidence and case-fatality risks (CFRs) for pneumococcal meningitis, NPNM IPD and pneumonia was obtained from WHO estimates for Mongolia [27]. These are summarised in Table 1; details of their estimation are in Supplementary material. Mongolia estimates were scaled by data from Philippines [28] and rural Thailand [29] for age-specific incidences. All-cause AOM incidence was obtained from a systematic review of published studies [30].

2.7. Hospitalization and health centre visit costs, out-of-pocket costs and productivity losses

Hospitalization costs were obtained from sources in Mongolia and are summarised in Table 1 with details in Supplementary material. Similarly for parameters of medical care-seeking for children with pneumonia and AOM [31,32].

To calculate productivity losses for caregivers of children under 18 years old, the average hospital stay or health centre visit was multiplied by the female labour force participation rate (58.4%) [33]. Each day of work lost was valued at Mongolia’s gross domestic product (GDP) per capita [34]. Out-of-pocket (OOP) expenditures were estimated using the WHO global health expenditure database [35] and a local pneumonia costing study. They included expenses for travel, additional drugs and tests and miscellaneous expenses as determined through patient surveys. They are summarised in Table 1 with details in Supplementary material.

2.8. Disability weights

Disability-adjusted life years (DALYs) lost due to non-fatal pneumococcal meningitis, pneumonia, NPNM IPD and AOM were obtained from the Global Burden of Disease [36] and the risk of different kinds of major sequelae of pneumococcal meningitis was obtained from a global meta-analysis [37], adjusted for WHO Western Pacific region (WPR). Further details of their estimation are in Supplementary material.
Indirect effects were extrapolated from IPD incidence following PCV13 introduction in the United Kingdom (UK) between 2010/11 and 2013/14 [38]. Based on UK observed data, age-dependent incidence prior to PCV7 introduction (2005/2006) was used as a baseline and proportional decrease in yearly age-dependent incidence from 2010 to 2014 were calculated. This proportional decline
All parameters of the base case and parameters in each of the scenarios where they differ from the base case have been highlighted in bold characters.


<table>
<thead>
<tr>
<th>Scenario</th>
<th>Vaccine cost</th>
<th>Hospitalization cost</th>
<th>Out-of-pocket cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base case</td>
<td>$3.30</td>
<td>$271.02</td>
<td>$4.48</td>
</tr>
<tr>
<td>S1: Max Gavi tail $</td>
<td>$3.50</td>
<td>$271.02</td>
<td>$4.48</td>
</tr>
<tr>
<td>S2: PAHO $</td>
<td>$15.68</td>
<td>$271.02</td>
<td>$4.48</td>
</tr>
<tr>
<td>S3: WHO-CHOICE</td>
<td>$3.30</td>
<td>$1,771.44</td>
<td>$5</td>
</tr>
<tr>
<td>S4: Low incid &amp; CFR</td>
<td>$3.30</td>
<td>$271.02</td>
<td>$4.48</td>
</tr>
<tr>
<td>S5: High incid &amp; CFR</td>
<td>$3.30</td>
<td>$271.02</td>
<td>$4.48</td>
</tr>
</tbody>
</table>

Parameters for various sensitivity scenarios and base case.

Case fatality risk

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Meningitis U5</th>
<th>Pneumonia IPD U5</th>
<th>NPNM U5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base case</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
<tr>
<td>S1: Max Gavi tail $</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
<tr>
<td>S2: PAHO $</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
<tr>
<td>S3: WHO-CHOICE</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
<tr>
<td>S4: Low incid &amp; CFR</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
<tr>
<td>S5: High incid &amp; CFR</td>
<td>0.346</td>
<td>0.054</td>
<td>0.271</td>
</tr>
</tbody>
</table>


All parameters of the base case and parameters in each of the scenarios where they differ from the base case have been highlighted in bold characters.

was applied to Mongolian incidence in the first four years of PCV introduction and we assumed constant proportion thereafter. Post-introduction surveillance in other countries [9,39] show the same qualitative trends, but UK data was used because it tracks the year-on-year change from baseline. Changes in incidence of vaccine-type and non-vaccine type IPD compared to the last year before vaccine introduction (2006/7) were used as indications of herd protection and serotype replacement, respectively. The direct effect of vaccination on vaccine-type disease was estimated as the product of vaccine efficacy for a 2 + 1 schedule in a high-income context. In the base case, given 97.6% coverage for 3 doses, 73.7% serotype coverage and 82.5% vaccine efficacy, indirect effects were assumed to be 88.6% of that in the UK.

2.10. Sensitivity analyses

To explore the robustness of conclusions to assumptions, the following sensitivity scenarios were modelled by varying costs and disease burden (Table 2):

i. Vaccine cost: Scenarios with higher vaccine purchase cost (a) Gavi AMC maximum tail price of $3.50 [8] and (b) the higher Pan American Health Organization (PAHO) Revolving Fund price of $15.68 [40]

ii. Hospitalization cost: As an upper limit for potential hospitalization costs, in the event of escalating costs, we include a scenario using outputs from WHO-CHOICE to estimate
hospitalization cost for pneumococcal meningitis, pneumonia or NPNM IPD. In a univariate linear regression model using the sample of available countries, GNI per capita significantly predicted average treatment cost for meningitis and pneumonia [41], with a reasonable model fit (R^2 of 83% for meningitis and 72% for pneumonia). Applying the regression estimates to 2013 GNI per capita for Mongolia ($3,770) [42], we estimated the average annual costs per hospitalized case for meningitis and pneumonia to be $1,771 and $528. NPNM IPD treatment cost was assumed to be the same as for meningitis. Out-of-pocket expenditures were calculated as before using a factor of 35% of Total Health Expenditure [35].

iii. Disease burden: A minimum-impact scenario for vaccine introduction with low disease rates and CFR, using lower bounds from WPR estimates, and conversely a maximum-impact scenario using upper bounds from WPR estimates were considered [43]. Regional lower and upper bound estimates per 100,000 were: pneumonia: 1381–2208; meningitis: 3–14; and NPNM IPD: 17–84 [43]. In all cases, incidence in the base case scenario was similar to the regional estimate or its lower bound. Lower and upper bounds for regional CFR estimates were: meningitis: 10–68%, pneumonia: 1–3% and severe NPNM IPD: 8–53% [43].

3. Results

3.1. Base case

The incremental cost-effectiveness ratio (ICER) per DALY averted from PCV13 introduction in Mongolia is estimated to be $52 from a health system perspective, and cost-saving from a societal perspective (Table 3). In an alternative conservative scenario that considers population direct effects only without herd effects due to reduced transmission (although herd effects of pneumococcal conjugate vaccines have been well-documented), introducing PCV13 is estimated to cost $79 from a health system perspective, and $19 from a societal perspective (Table 3).

3.2. Sensitivity analyses

Table 4 shows how the cost per DALY averted from PCV13 vaccination may change for the scenarios considered in the sensitivity analyses. The most pessimistic scenario was purchase of PCV13 at the higher PAHO price, which cost $460 and $390 per DALY averted from health system and societal perspectives, respectively ($540 and $480, respectively, when considering the unlikely but further conservative case of population direct effects only from vaccine). The minimum impact scenario that considered the conservative lower bounds of disease incidence and CFRs, cost $110 per DALY averted from a health system perspective and was cost-saving from a societal perspective. Additional, one-way sensitivity analyses varying vaccine-related parameters, disease burden and disability weights by ±25% also showed PCV13 vaccination to be cost-effective (Tornado diagram, see Supplementary figure).

3.3. Budget impact

Fig. 2 displays the impact that vaccination with PCV13 may have on the health care budget for MOH, as well as on wider societal costs, in 2014 US$ (i.e., not considering inflation). A constant birth cohort size and no vaccine price maturation were assumed. Vaccination with PCV13 is expected to cost around $920,000 in the first year assuming increase in cold chain capacity, and thereafter cost around $820,000 every year. The vaccination programme is likely to reduce direct costs to the health care budget by about $440,000 in the first year, increasing to $510,000 by 2025. Societal costs, which includes productivity losses and out-of-pocket expenses, are also likely to be reduced by about $380,000 in 2016, rising to $480,000 by 2025.
4. Discussion

The ICER for PCV13 introduction in Mongolia—$52 per DALY averted and cost-saving from health care provider and societal perspectives, respectively—is substantially lower than Mongolia’s GDP per capita ($4,056.40 in 2013) sometimes used as a threshold for cost-effectiveness [34], as well as a much lower threshold of $122–$173 suggested by the University of York based on the mortality effects of health expenditure [44]. It also compares favourably to previously estimated ICERS of $114–$123 per DALY for rotavirus vaccination [45] and $470 per DALY for HPV vaccination at Gavi prices [46]; and $91–$110 per DALY from a regional analysis for Hib vaccine [41]. Hence PCV13 introduction is likely to be a cost-effective decision for Mongolia. The ICER of PCV13 introduction remains well below GDP per capita (and usually below the other thresholds examined) across the range of potential scenarios considered.

Our study is the first country-specific PCV cost-effectiveness evaluation in Mongolia, but is consistent with more general analyses. For example, one study concluded that using PCV in the 72 Gavi-eligible countries in 2005 would have an ICER of about $100 per DALY prevented; this analysis used the societal perspec-
tive and considered direct population effects only [47]. The corre-
sponding ICER from our analysis for Mongolia was $19. While care
should be taken in comparing results from economic models, this
suggests that PCV13 is indeed highly cost-effective for Mongolia.

The price at which PCV13 is being offered through Gavi is a
major factor in making PCV13 highly cost-effective or cost-saving
for introduction in Mongolia. Although the price is low relative
to prices offered for PCV13 globally, the total vaccine cost to the
country still amounts to $920,000 in the first year due to additional
cold chain capacity costs for PCV and $820,000 per year in subse-
quent years for national introduction. Furthermore, even at the
higher PAHO revolving fund price, which we do not reasonably
expect Mongolia’s vaccine purchase price to exceed even after
transition out of Gavi’s AMC price, PCV13 introduction was highly
cost-effective. In addition to vaccine cost, disease incidence was a
major driver influencing the cost-effectiveness analysis. However,
evén at lower bounds of incidence and case fatality risk, introd-
cution of PCV13 was cost-effective for Mongolia.

Mongolian public expenditure on health in 2014 is 2.6% of GDP,
which is around three hundred million dollars. As seen from the
budget impact analysis, total yearly PCV13 vaccine costs to the
country represents approximately 0.3% of the annual public spend-
ing on health. While this is not trivial sum, a decreased pneumo-
coccal disease burden from PCV vaccination is estimated to
reduce disease-related spending by $500,000. Furthermore, when
economic costs to the wider society are considered, additional sav-
ings of $400,000 per year results in an annual potential budget saving
of around $100,000 to $200,000.

A limitation of this analysis was an absence of local data for age-
specific disease burden, as it is common in many low and middle
income countries with limited resources for bacteriological surve-
illance. Data from the Philippines and Thailand was thus
extrapolated based on inter-country similarities in terms of GNI per capita, life expectancy, proportion of deaths from and health-
seeking for respiratory infections, etc. (see Supplementary mate-
rial. Country profiles). Availability of local data would enhance the
representativeness of this analysis. However, our results are
robust to varying the parameters extrapolated from other settings
within large ranges representing the range of values of countries in
the WPR. Hence our analysis suggests ways that useful conclusions
can be drawn from economic evaluations in countries with limited
epidemiological data. More local data would also allow us to con-
duct probabilistic sensitivity analyses to assess uncertainty of all
parameters together.

Finally, some assumptions were made regarding the health sys-
tem’s capacity for effective delivery of this additional vaccine
including necessary investments to maintain the quality of surveil-
ance for adverse events following immunization, supply distribu-
tion systems and monitoring. Furthermore, other healthcare costs,
such as training, social mobilization and surveillance capacity
building prior to vaccine introduction were not included. Our
model therefore underestimates the administrative costs of vac-
cine introduction. However, these costs are expected to be small
relative to the costs of vaccine and related supplies.

Recently, MOH and WHO in Mongolia have discussed using a 2
+ 1 vaccine schedule instead of the originally planned 3 + 0 sched-
ule [7], which this analysis is based on. Since, number of vaccine
doses remains unchanged and no significant differences in impact
on disease burden between schedules have been currently
established [48,49], we do not expect the conclusions to change
for a 2 + 1 schedule.

In conclusion, routine infant vaccination against *S. pneumoniae*
with PCV13 appears to be highly cost-effective when compared
to no vaccination in Mongolia. Continued investment in this vacci-
nation programme is likely to be the right economic decision
despite the present financial challenges in Mongolia.

Conflict of interest

The authors have no conflict of interest to declare.

Acknowledgments

We thank Mongolia’s Ministry of Health for their support, advice
and convening of experts to guide model development. We also
especially thank Dr. D. Sodbayar (World Health Organiza-
tion), Dr. D. Gantulga (NCCD), Ms. Narangav (NCCD), Mr. Shineba-
yar (NCCD), Dr. G. Surenkhand (NCCD), Dr. D. Narangerel (Public
Health Unit and national EPI manager).

A special thanks to Dr. Kip Baggett (Thailand Ministry of Public
Health – U.S. Centers for Disease Control and Prevention Collabo-
ration) for data on pneumonia in Thailand, Dr. Thomas Cherian
(WHO) and Prof. Elizabeth Miller (Public Health England) for help-
ful discussions about evidence around the effectiveness of pneu-
mococcal vaccines.

This study was funded by the World Health Organization, Gen-
eva and Gavi, the Vaccine Alliance. The WHO Regional Office for
the Western Pacific provided travel support. The authors alone are
responsible for the views expressed in this publication and they
do not necessarily represent the decisions, policy or views of the
World Health Organization. Nothing in this report should be con-
strued as an endorsement by WHO or any other organization of
any product.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.12.
070.

References

[3] Altugareel E. Air pollution is endangering children’s health in Mongolia. 22
health/mongolia_50290.html> [accessed 27/04/2016].
and etiology of childhood pneumonia in 2010: estimates of incidence, severe
morbidity, mortality, underlying risk factors and causative pathogens for 192
Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia:
58–511.
NVS – PCV support: Mongolia <http://www.gavi.org/country/mongolia/
documents/approved-proposal> [accessed 04/05/2016].
apply/graduating-countries> [accessed 03/05/2016].
[9] Centers for Disease Control and Prevention. Direct and indirect effects of
routine vaccination of children with 7-valent pneumococcal conjugate vaccine
[10] Miller E, Andrews NJ, Waite PA, Slack MP, George RC. Herb immunity and
serotype replacement 4 years after seven-valent pneumococcal conjugate
vaccination in England and Wales: an observational cohort study. Lancet Infect
[12] Tan Torres-Edejer T. Making choices in health: WHO guide to cost-
Observatory Data Repository; 2011.